Neurologic DisordersNeurEYE-URJCNCT07909824
Advanced Multisensorial System for Automatic Assessment of Neurological Disorders in Smart Spaces-Universidad Rey Juan Carlos (URJC)
An observational study of Neurologic Disorders, run by Universidad Rey Juan Carlos at 1 site in Spain.
Trial summary
Neurological diseases affect people's cognitive and physical abilities, limiting their functional independence and causing disability, which in many cases, is progressive and degenerative. Being able to perform activities of daily living is a challenge in these pathologies. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Neurologic Disorders
- What is being tested?
- NeurEYE: healthy people and NeurEYE: people with neurological diseases
- Type of treatment
- Medical device
- How many people
- 50 participants
- Where
- 1 siteSpain
- Study dates
- Nov 2026to Nov 2028
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The Control group sample (subjects without pathology over the age of 18) will be obtained using non-probability convenience sampling. Recruitment will be carried out from the researchers' immediate circle. The experimental group sample (adults diagnosed with a neurological disease) is proposed through a non-probabilistic sampling of consecutive cases from collaborating hospitals and patient associations [Spanish Federation of Parkinson's Disease Associations, the Synaptia Vithas Neuroscience Institute, the University Hospital of Guadalajara and the National Paraplegic Hospital of Toledo].
Who may be able to join
- Time since diagnosis.
- Mini-Mental State Examination (Folstein) score between 10 and 30 (no impairment or moderate cognitive impairment).
- Barthel Index score between 100 and 61 (independent or mildly dependent).
- On stable medical treatment for three months prior to assessment.
Who cannot join
- Diagnosis of a musculoskeletal disorder or diagnosis of any cardiovascular, respiratory, or metabolic disease, or other conditions that may interfere.
- Failure to sign the informed consent form.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site
Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos
Alcorcón, Madrid, 28922
Marta Pérez de Heredia Torres, PhD, +34914888886, marta.perezdeheredia@urjc.es
Rosa M Martínez Piédrola, PhD, +3491488887, rosa.martinez@urjc.es
About this study
Official title: Advanced Multisensorial System for Automatic Assessment of Neurological Disorders in Smart Spaces-URJC
Neurological diseases affect people's cognitive and physical abilities, limiting their functional independence and causing disability, which in many cases, is progressive and degenerative. Being able to perform activities of daily living is a challenge in these pathologies. Currently, different observational tools are administered to assess the degree of functional limitation in basic and instrumental Activities of Daily Living (ADL). However, the assessment must be performed in an ecological and real context to obtain objective information and ensure the most accurate assessment possible. To this end, it is necessary to consider the factors that influence the performance of ADLs and also on the quality of their execution, especially in this population in which the stressful situation of direct observation by an evaluator has a direct influence on the final score. Advanced Multisensorial System for Automatic Assessment of Neurological Disorders in Smart Spaces (NeurEYE) aims to develop technological tools to extract from sensory systems typical of intelligent spaces and with the help of signal processing and machine learning processes based on artificial intelligence, indicators of neurological impairment that influence functional capacity and function/dysfunction components while observing the performance of an activity of daily living. In addition, NeurEYE would provide as a scientific breakthrough the accurate description of subjects' limitations in the controlled assessment environment within the routine patient context. The NeurEye project will allow the clinical validation of a multisensory system that, through the detection of functional limitations in the ADLs of patients with neurological disorder, allows to establish the level of disability of the subjects. In addition, the qualitative and quantitative description of the functional alterations of the person with neurological disorders and, the elimination of the subjective bias of the examiner, will allow the generation of individualized clinical and statistical reports according to sex, activity, etc. that will be clinically useful in the early detection, diagnosis, and adaptation of rehabilitation treatments to the specific functional needs of neurological disorders.
Read the detailed description
The project has been funded by the Ministry of Science, Innovation and universities in the 2023 Call - "Knowledge Generation Projects" and actions for the training of predoctoral research staff associated with these projects. The Advanced Multisensorial System for Automatic Assessment of Neurological Disorders in Smart Spaces - Universidad Rey Juan Carlos (NeurEYE-URJC) project ref. PID2024-156576OB-C32 is part of a combined project with the University of Seville and the University of Alcalá de Henares. The NeurEYE-URJC project plays a leading role in the design of the methodology, and clinical validation, with the collaboration of the NeurEYE-Universidad de Alcalá (NeurEYE-UAH) and NeurEYE-Universidad de Sevilla (NeurEYE-US) projects being necessary to provide detailed feedback on the current and foreseeable possibilities of cutting-edge technology for the analysis of human behaviour. This proposal is linked to the "Health" priority of the State Plan for Scientific Research. In addition, the project is also directed towards the second pillar of the Global Challenges within those of Horizon Europe. More specifically, towards some of the main objectives of the Health Cluster.
Neurological diseases are one of the main causes of disability. In Spain, this type of pathology is responsible for 44% of disability due to chronic diseases and 50% of the years lost due to disability. ADLs are fundamental skills for maintaining and caring for oneself, therefore, the inability to perform them properly results in a state of dependency, which implies the need for some kind of help or assistance and, therefore, entails high financial and care costs.
However, there are important limitations in their application: first, no "gold standard" has been determined for the evaluation of functionality, second, the information they detail is not related to the quality of execution, third, they have practical limitations such as long administration times, fourth, the subjectivity of the evaluator and the biases it produces; gender and culture, interviewee biases for feeling observed by another person and in the case of interviews, recall biases that can occur in self-administered tools, because they are based on the recall of performance in the ADL and we can find that those who are evaluated consider their problem as unimportant, are aware of their problem but deny it or do not report it accurately and/or realistically. In addition, we may encounter evaluator bias, since observational assessment instruments require professional training to administer them.
The use of technology is an innovative strategy that can bring great improvements in the evaluation of functional performance, as it can objectively measure performance in an activity and the required behaviors through para-based monitoring.
- Conditions
- Neurologic Disorders
- Being tested
- NeurEYE: healthy people, NeurEYE: people with neurological diseases
- Keywords
- Automatic assessment of functional limitations, Neurological disorders,, Activities of daily living, Behavior analysis, Smart spaces, Audiovisual sensors and wearables, Artificial intelligence, Machine learning
- Medical subject headings
- Nervous System Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NeurEYE: healthy peopleDevice
The data to be captured are exclusively video and audio recordings, and different signals from smartwatches (mainly related to movement).
Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project.
The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment.
NeurEYE: people with neurological diseasesDevice
The data to be captured are exclusively video andaudio recordings, and different signals from smartwatches (mainly related to movement).
Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to theassessment scales to be defined in the project.
The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment.
| Study group | Role | What they receive |
|---|---|---|
| Healthy people | Undiagnosed persons will be evaluated by the NeurEYE system performing activities of daily living.
Patterns of action will be recorded to establish outcome measures in healthy population. Receives: Device: NeurEYE: healthy people | |
| People with neurological diseases | People with neurological diseases will be evaluated by the NeurEYE system performing activities of daily living.
Patterns of action will be recorded, to establish outcome measures in healthy population. Receives: Device: NeurEYE: people with neurological diseases |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognitive assessment
Rivermead Behavioural Memory Test (RBMT) is a standardized memory assessment tool designed to evaluate how memory problems affect a person's daily functioning. It primarily assesses prospective memory, verbal memory, visual memory, recognition, and orientation through tasks that simulate everyday situations.
It is a widely used test in clinical and research settings, with adequate psychometric properties (reliability and validity) and sensitivity for detecting memory impairments associated with brain damage, neurodegenerative diseases, and other neurological conditions.
It is administered individually by a trained professional. It includes various functional tasks, such as recalling names, routes, messages, or personal belongings.
Measured: First year
Grip strength assessment
To measure grip strength the Jamar dynamometer is a standardized instrument used to measure handgrip strength, a relevant indicator of upper limb muscle function and overall functional status. It is frequently used in rehabilitation, neurology, geriatrics, and musculoskeletal assessment.
It is considered the gold standard for grip strength assessment. It exhibits high reliability, validity, and reproducibility, making it widely used in both clinical practice and research.
Measured: First year
Manual dexterity
The Nine Hole Peg Test (NHPT) is a standardized test used to assess fine motor dexterity and upper limb motor coordination. It measures how quickly a person can place and remove nine pegs from a pegboard and is widely used in neurology and rehabilitation.
It is a well-validated tool with good reliability, validity, and sensitivity for detecting changes in manual function. It is frequently used in research and clinical practice with populations affected by stroke, multiple sclerosis, Parkinson's disease, and other neurological conditions.
Measured: First year
Cognitive abilities
The Trail Making Test (TMT) is a standardized neuropsychological test that assesses processing speed, visual attention, cognitive flexibility, and executive functions. It can be administered by occupational therapists. It consists of two parts: Part A involves connecting numbers in sequence, and Part B involves alternating numbers and letters in a predetermined order.
It is one of the most widely used and validated tests in neuropsychology. It exhibits adequate psychometric properties, good reliability, and sensitivity for detecting cognitive impairments associated with brain damage, aging, dementia, and other neurological diseases.
Measured: First year
Language
The Quick Aphasia Battery (QAB) is an standardized tool designed to quickly assess the presence and severity of language impairments in individuals with aphasia. It evaluates various language domains, including auditory comprehension, verbal expression, repetition, naming, reading, and language fluency.
It is a validated test with good psychometric properties, allowing for the reliable identification and quantification of language deficits. It has proven useful in both clinical and research settings, particularly in patients with stroke and other acquired neurological injuries.
Measured: First year
Behavioral
Lille Apathy Rating Scale (LARS) is a standardized tool designed to assess apathy in individuals with neurological disorders. It analyzes different dimensions of this syndrome, including motivation, interest, initiative, participation in activities, and emotional response.
It is a widely used and validated scale, especially in Parkinson's disease and other neurological conditions. It exhibits good internal consistency, high inter-rater reliability, and adequate construct and criterion validity, allowing for the reliable identification and quantification of apathy severity.
Measured: First Year
Depression
Mini-DASS (Mini Depression Anxiety Stress Scales). Designed to assess emotional distress across three main dimensions: depression, anxiety, and stress. It is used as a screening tool to identify emotional symptoms and monitor changes over time.
It is a measure based on the theoretical model of the Depression Anxiety Stress Scales, which has been widely validated in general and clinical populations. The abbreviated versions have shown adequate validity and reliability, maintaining a good ability to discriminate between depressive, anxious, and stress symptoms.
Good internal consistency for the total score and its subscales, with Cronbach's alpha coefficients generally above 0.70. Adequate convergent validity with other measures of depression, anxiety, and emotional well-being. Good sensitivity for detecting mild, moderate, and high levels of psychological distress. A factor structure consistent with the dimensions of depression, anxiety
Measured: First year
Apraxia
Test of Upper Limb Apraxia (TULIA). This is a standardized tool designed to assess upper limb apraxia, that is, difficulties in planning and executing learned movements voluntarily despite preserving basic strength, sensation, and comprehension. It evaluates the imitation and execution of both transitive (object use) and intransitive (communicative) movements.
It is a widely validated test for the assessment of apraxia following stroke and other neurological injuries. It exhibits high reliability, validity, and discriminative power, making it one of the reference tools for the clinical and research assessment of upper limb apraxia.
Measured: First Year
Attentional deficit
Star Cancellation Test is a screening test used to assess unilateral spatial hemineglect, a common impairment following brain injury, especially after a right hemisphere stroke. It evaluates a person's ability to visually explore space and identify stimuli distributed on a sheet of paper.
It is one of the most widely used tests for detecting spatial hemineglect. It has demonstrated good clinical validity and sensitivity for identifying visuospatial attention deficits, and is included in widely used batteries in neurology and neurorehabilitation, such as the Behavioral Inattention Test (BIT).
Measured: First Year
Sensibility 1
Algometry (pressure pain threshold measurement) is a standardized technique used to assess sensitivity to mechanical pain by measuring the pressure pain threshold (PPT). It allows for the objective quantification of the minimum pressure that elicits a painful sensation and is frequently used in patients with musculoskeletal disorders, chronic pain, and neurological conditions.
Algometry is a widely used method in research and clinical practice for pain assessment. It exhibits good validity and reliability when performed with standardized protocols, and is particularly useful for monitoring changes in pain sensitivity and response to treatments.
Measured: First year
Sensibility 2
The Visual Analogue Scale (VAS) is a self-report tool used to evaluate the intensity of perceived pain. It typically consists of a 10 cm line whose ends represent "no pain" and "worst imaginable pain," allowing for a simple quantification of the subjective experience of pain.
It is one of the most widely used pain measures in clinical practice and research. It exhibits adequate validity, reliability, and sensitivity to change, and is considered a gold standard for assessing pain intensity and monitoring the response to therapeutic interventions.
Measured: Second year
Motor function
Box and Block Test (BBT) This is a standardized test used to assess gross manual dexterity and unilateral upper extremity motor function. It measures a person's ability to grasp, carry, and release wooden blocks from one compartment to another within a specified time.
It is one of the most widely used tools for assessing manual function in rehabilitation, neurology, and occupational therapy. It exhibits strong psychometric properties and is sensitive in detecting motor deficits and functional changes following therapeutic intervention.
Measured: First year
Functional gait
Functional Gait Assessment (FGA) is an observational scale designed to assess functional gait and dynamic balance during various tasks that challenge postural control. It analyzes an individual's ability to walk under different conditions, such as changes in speed, head turns, walking with obstacles, quick turns, and stair climbing.
It is a widely used tool in neurology, geriatrics, and rehabilitation. Derived from the Dynamic Gait Index (DGI), it exhibits good psychometric properties and a high capacity for identifying dynamic balance impairments and fall risk in individuals with neurological and vestibular disorders.
Measured: First Year
Postural control
Sensory Organization Test (SOT). This instrumental test assesses postural control and balance by analyzing how a person uses and integrates visual, vestibular, and somatosensory information to maintain stability. It is one of the most widely used tests within computerized dynamic posturography.
The SOT is considered a gold standard for the objective assessment of balance. It has high validity and reliability and is widely used in research and clinical practice to evaluate balance impairments associated with neurological, vestibular, and musculoskeletal disorders.
Measured: First year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2026
- Study startNov 2026 (estimated)
- Primary completionNov 2026 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neurologic DisordersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 50 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Universidad Rey Juan Carlos
- Sponsor type
- University, hospital or other
- Collaborators
- University of Seville, University of Alcala
- Responsible party
- Principal investigator, Rosa M Martínez Piédrola, Universidad Rey Juan Carlos
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07909824
- Sponsor's protocol ID
- A726
- Other IDs
- 2025/00420/006, 2025
- Acronym
- NeurEYE-URJC
- Status last verified
- Oct 2026
- First submitted
- 26 Oct 2026
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No personal data of participants will be shared
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Advanced Multisensorial System for Automatic Assessment of Neurological Disorders in Smart Spaces-URJC
- ClinicalTrials.gov ID
- NCT07909824
- Acronym / sponsor ID
- NeurEYE-URJC / A726
- Conditions
- Neurologic Disorders
- Keywords
- Automatic assessment of functional limitations, Neurological disorders,, Activities of daily living, Behavior analysis, Smart spaces, Audiovisual sensors and wearables, Artificial intelligence, Machine learning
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Universidad Rey Juan CarlosUniversity, hospital or other
- Collaborators
- University of Seville, University of Alcala
- Study start
- Nov 2026 (estimated)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2028 (estimated)
- First posted
- 2 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Neurological diseases affect people's cognitive and physical abilities, limiting their functional independence and causing disability, which in many cases, is progressive and degenerative. Being able to perform activities of daily living is a challenge in these pathologies. Currently, different observational tools are administered to assess the degree of functional limitation in basic and instrumental Activities of Daily Living (ADL). However, the assessment must be performed in an ecological and real context to obtain objective information and ensure the most accurate assessment possible. To this end, it is necessary to consider the factors that influence the performance of ADLs and also on the quality of their execution, especially in this population in which the stressful situation of direct observation by an evaluator has a direct influence on the final score. Advanced Multisensorial System for Automatic Assessment of Neurological Disorders in Smart Spaces (NeurEYE) aims to develop technological tools to extract from sensory systems typical of intelligent spaces and with the help of signal processing and machine learning processes based on artificial intelligence, indicators of neurological impairment that influence functional capacity and function/dysfunction components while observing the performance of an activity of daily living. In addition, NeurEYE would provide as a scientific breakthrough the accurate description of subjects' limitations in the controlled assessment environment within the routine patient context. The NeurEye project will allow the clinical validation of a multisensory system that, through the detection of functional limitations in the ADLs of patients with neurological disorder, allows to establish the level of disability of the subjects. In addition, the qualitative and quantitative description of the functional alterations of the person with neurological disorders and, the elimination of the subjective bias of the examiner, will allow the generation of individualized clinical and statistical reports according to sex, activity, etc. that will be clinically useful in the early detection, diagnosis, and adaptation of rehabilitation treatments to the specific functional needs of neurological disorders.
Detailed description
The project has been funded by the Ministry of Science, Innovation and universities in the 2023 Call - "Knowledge Generation Projects" and actions for the training of predoctoral research staff associated with these projects. The Advanced Multisensorial System for Automatic Assessment of Neurological Disorders in Smart Spaces - Universidad Rey Juan Carlos (NeurEYE-URJC) project ref. PID2024-156576OB-C32 is part of a combined project with the University of Seville and the University of Alcalá de Henares. The NeurEYE-URJC project plays a leading role in the design of the methodology, and clinical validation, with the collaboration of the NeurEYE-Universidad de Alcalá (NeurEYE-UAH) and NeurEYE-Universidad de Sevilla (NeurEYE-US) projects being necessary to provide detailed feedback on the current and foreseeable possibilities of cutting-edge technology for the analysis of human behaviour. This proposal is linked to the "Health" priority of the State Plan for Scientific Research. In addition, the project is also directed towards the second pillar of the Global Challenges within those of Horizon Europe. More specifically, towards some of the main objectives of the Health Cluster.
Neurological diseases are one of the main causes of disability. In Spain, this type of pathology is responsible for 44% of disability due to chronic diseases and 50% of the years lost due to disability. ADLs are fundamental skills for maintaining and caring for oneself, therefore, the inability to perform them properly results in a state of dependency, which implies the need for some kind of help or assistance and, therefore, entails high financial and care costs.
However, there are important limitations in their application: first, no "gold standard" has been determined for the evaluation of functionality, second, the information they detail is not related to the quality of execution, third, they have practical limitations such as long administration times, fourth, the subjectivity of the evaluator and the biases it produces; gender and culture, interviewee biases for feeling observed by another person and in the case of interviews, recall biases that can occur in self-administered tools, because they are based on the recall of performance in the ADL and we can find that those who are evaluated consider their problem as unimportant, are aware of their problem but deny it or do not report it accurately and/or realistically. In addition, we may encounter evaluator bias, since observational assessment instruments require professional training to administer them.
The use of technology is an innovative strategy that can bring great improvements in the evaluation of functional performance, as it can objectively measure performance in an activity and the required behaviors through para-based monitoring.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Target follow-up
- 3 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Healthy people | – | Device: NeurEYE: healthy peopleUndiagnosed persons will be evaluated by the NeurEYE system performing activities of daily living. Patterns of action will be recorded to establish outcome measures in healthy population. |
| People with neurological diseases | – | Device: NeurEYE: people with neurological diseasesPeople with neurological diseases will be evaluated by the NeurEYE system performing activities of daily living. Patterns of action will be recorded, to establish outcome measures in healthy population. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The Control group sample (subjects without pathology over the age of 18) will be obtained using non-probability convenience sampling. Recruitment will be carried out from the researchers' immediate circle. The experimental group sample (adults diagnosed with a neurological disease) is proposed through a non-probabilistic sampling of consecutive cases from collaborating hospitals and patient associations [Spanish Federation of Parkinson's Disease Associations, the Synaptia Vithas Neuroscience Institute, the University Hospital of Guadalajara and the National Paraplegic Hospital of Toledo].
Key inclusion criteria (4 listed)
- Time since diagnosis.
- Mini-Mental State Examination (Folstein) score between 10 and 30 (no impairment or moderate cognitive impairment).
- Barthel Index score between 100 and 61 (independent or mildly dependent).
- On stable medical treatment for three months prior to assessment.
Key exclusion criteria (2 listed)
- Diagnosis of a musculoskeletal disorder or diagnosis of any cardiovascular, respiratory, or metabolic disease, or other conditions that may interfere.
- Failure to sign the informed consent form.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NeurEYE: healthy peopleThe data to be captured are exclusively video and audio recordings, and different signals from smartwatches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment. | Device | Healthy people |
| NeurEYE: people with neurological diseasesThe data to be captured are exclusively video andaudio recordings, and different signals from smartwatches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to theassessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment. | Device | People with neurological diseases |
Primary outcome
Cognitive assessment
Time frame: First year
Rivermead Behavioural Memory Test (RBMT) is a standardized memory assessment tool designed to evaluate how memory problems affect a person's daily functioning. It primarily assesses prospective memory, verbal memory, visual memory, recognition, and orientation through tasks that simulate everyday situations. It is a widely used test in clinical and research settings, with adequate psychometric properties (reliability and validity) and sensitivity for detecting memory impairments associated with brain damage, neurodegenerative diseases, and other neurological conditions. It is administered individually by a trained professional. It includes various functional tasks, such as recalling names, routes, messages, or personal belongings.
Grip strength assessment
Time frame: First year
To measure grip strength the Jamar dynamometer is a standardized instrument used to measure handgrip strength, a relevant indicator of upper limb muscle function and overall functional status. It is frequently used in rehabilitation, neurology, geriatrics, and musculoskeletal assessment. It is considered the gold standard for grip strength assessment. It exhibits high reliability, validity, and reproducibility, making it widely used in both clinical practice and research.
Manual dexterity
Time frame: First year
The Nine Hole Peg Test (NHPT) is a standardized test used to assess fine motor dexterity and upper limb motor coordination. It measures how quickly a person can place and remove nine pegs from a pegboard and is widely used in neurology and rehabilitation. It is a well-validated tool with good reliability, validity, and sensitivity for detecting changes in manual function. It is frequently used in research and clinical practice with populations affected by stroke, multiple sclerosis, Parkinson's disease, and other neurological conditions.
Cognitive abilities
Time frame: First year
The Trail Making Test (TMT) is a standardized neuropsychological test that assesses processing speed, visual attention, cognitive flexibility, and executive functions. It can be administered by occupational therapists. It consists of two parts: Part A involves connecting numbers in sequence, and Part B involves alternating numbers and letters in a predetermined order. It is one of the most widely used and validated tests in neuropsychology. It exhibits adequate psychometric properties, good reliability, and sensitivity for detecting cognitive impairments associated with brain damage, aging, dementia, and other neurological diseases.
Language
Time frame: First year
The Quick Aphasia Battery (QAB) is an standardized tool designed to quickly assess the presence and severity of language impairments in individuals with aphasia. It evaluates various language domains, including auditory comprehension, verbal expression, repetition, naming, reading, and language fluency. It is a validated test with good psychometric properties, allowing for the reliable identification and quantification of language deficits. It has proven useful in both clinical and research settings, particularly in patients with stroke and other acquired neurological injuries.
Behavioral
Time frame: First Year
Lille Apathy Rating Scale (LARS) is a standardized tool designed to assess apathy in individuals with neurological disorders. It analyzes different dimensions of this syndrome, including motivation, interest, initiative, participation in activities, and emotional response. It is a widely used and validated scale, especially in Parkinson's disease and other neurological conditions. It exhibits good internal consistency, high inter-rater reliability, and adequate construct and criterion validity, allowing for the reliable identification and quantification of apathy severity.
Depression
Time frame: First year
Mini-DASS (Mini Depression Anxiety Stress Scales). Designed to assess emotional distress across three main dimensions: depression, anxiety, and stress. It is used as a screening tool to identify emotional symptoms and monitor changes over time. It is a measure based on the theoretical model of the Depression Anxiety Stress Scales, which has been widely validated in general and clinical populations. The abbreviated versions have shown adequate validity and reliability, maintaining a good ability to discriminate between depressive, anxious, and stress symptoms. Good internal consistency for the total score and its subscales, with Cronbach's alpha coefficients generally above 0.70. Adequate convergent validity with other measures of depression, anxiety, and emotional well-being. Good sensitivity for detecting mild, moderate, and high levels of psychological distress. A factor structure consistent with the dimensions of depression, anxiety
Apraxia
Time frame: First Year
Test of Upper Limb Apraxia (TULIA). This is a standardized tool designed to assess upper limb apraxia, that is, difficulties in planning and executing learned movements voluntarily despite preserving basic strength, sensation, and comprehension. It evaluates the imitation and execution of both transitive (object use) and intransitive (communicative) movements. It is a widely validated test for the assessment of apraxia following stroke and other neurological injuries. It exhibits high reliability, validity, and discriminative power, making it one of the reference tools for the clinical and research assessment of upper limb apraxia.
Attentional deficit
Time frame: First Year
Star Cancellation Test is a screening test used to assess unilateral spatial hemineglect, a common impairment following brain injury, especially after a right hemisphere stroke. It evaluates a person's ability to visually explore space and identify stimuli distributed on a sheet of paper. It is one of the most widely used tests for detecting spatial hemineglect. It has demonstrated good clinical validity and sensitivity for identifying visuospatial attention deficits, and is included in widely used batteries in neurology and neurorehabilitation, such as the Behavioral Inattention Test (BIT).
Sensibility 1
Time frame: First year
Algometry (pressure pain threshold measurement) is a standardized technique used to assess sensitivity to mechanical pain by measuring the pressure pain threshold (PPT). It allows for the objective quantification of the minimum pressure that elicits a painful sensation and is frequently used in patients with musculoskeletal disorders, chronic pain, and neurological conditions. Algometry is a widely used method in research and clinical practice for pain assessment. It exhibits good validity and reliability when performed with standardized protocols, and is particularly useful for monitoring changes in pain sensitivity and response to treatments.
Sensibility 2
Time frame: Second year
The Visual Analogue Scale (VAS) is a self-report tool used to evaluate the intensity of perceived pain. It typically consists of a 10 cm line whose ends represent "no pain" and "worst imaginable pain," allowing for a simple quantification of the subjective experience of pain. It is one of the most widely used pain measures in clinical practice and research. It exhibits adequate validity, reliability, and sensitivity to change, and is considered a gold standard for assessing pain intensity and monitoring the response to therapeutic interventions.
Motor function
Time frame: First year
Box and Block Test (BBT) This is a standardized test used to assess gross manual dexterity and unilateral upper extremity motor function. It measures a person's ability to grasp, carry, and release wooden blocks from one compartment to another within a specified time. It is one of the most widely used tools for assessing manual function in rehabilitation, neurology, and occupational therapy. It exhibits strong psychometric properties and is sensitive in detecting motor deficits and functional changes following therapeutic intervention.
Functional gait
Time frame: First Year
Functional Gait Assessment (FGA) is an observational scale designed to assess functional gait and dynamic balance during various tasks that challenge postural control. It analyzes an individual's ability to walk under different conditions, such as changes in speed, head turns, walking with obstacles, quick turns, and stair climbing. It is a widely used tool in neurology, geriatrics, and rehabilitation. Derived from the Dynamic Gait Index (DGI), it exhibits good psychometric properties and a high capacity for identifying dynamic balance impairments and fall risk in individuals with neurological and vestibular disorders.
Postural control
Time frame: First year
Sensory Organization Test (SOT). This instrumental test assesses postural control and balance by analyzing how a person uses and integrates visual, vestibular, and somatosensory information to maintain stability. It is one of the most widely used tests within computerized dynamic posturography. The SOT is considered a gold standard for the objective assessment of balance. It has high validity and reliability and is widely used in research and clinical practice to evaluate balance impairments associated with neurological, vestibular, and musculoskeletal disorders.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
- Individual participant dataSharing planned: No. No personal data of participants will be shared
Related trials for Neurologic Disorders
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Aphasia (BG-Aphasia-01)
Expressive Aphasia, Aphasia Following Cerebral Infarction
Not yet recruiting
Feasibility of a Robot-Guided Active Play Intervention for Children With Cerebral Palsy
Cerebral Palsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neurologic Disorders, run by Universidad Rey Juan Carlos at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marta Pérez de Heredia Torres, PhD (+34914888886, marta.perezdeheredia@urjc.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognitive assessment (time frame: First year). The study lists 14 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.